Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Human Vaccines & Immunotherapeutics|January 28, 2015
IMA901: a multi-peptide cancer vaccine for treatment of renal cell cancerAlexandra Kirner, Andrea Mayer-Mokler, Carsten Reinhardt
European Radiology|June 23, 2022
Adjacent cartilage tissue structure after successful transplantation: a quantitative MRI study using T<sub>2</sub> mapping and texture analysisVeronika Janacova, Pavol Szomolanyi, Alexandra Kirner, et al.
Behavioural Brain Research|January 16, 2003
Concanavalin A application to the olfactory epithelium reveals different sensory neuron populations for the odour pair D- and L-carvoneAlexandra Kirner, Swetlana Deutsch, Elke Weiler, et al.
Orthopaedic Journal of Sports Medicine|September 1, 2023
Comparison of Hydrogel-Based Autologous Chondrocyte Implantation Versus Microfracture: A Propensity Score Matched-Pair AnalysisPhilipp Niemeyer, Peter Angele, Robert C Spiro, et al.
Cartilage|January 30, 2025
Texture Analysis of Cartilage Repair Tissue Maturation: Comparison of Two Cartilage Repair Methods and Correlation with MOCART 2.0Veronika Janacova, Pavol Szomolanyi, Diana Sitarcikova, et al.
Cartilage|July 16, 2021
Differentiation of Cartilage Repair Techniques Using Texture Analysis from T<sub>2</sub> MapsVladimir Juras, Pavol Szomolanyi, Veronika Janáčová, et al.
Cartilage|March 19, 2024
Hydrogel-Based Matrix-Associated Autologous Chondrocyte Implantation Shows Greater Substantial Clinical Benefit at 24 Months Follow-Up than Microfracture: A Propensity Score Matched-Pair AnalysisChristoph Gaissmaier, Peter Angele, Robert C Spiro, et al.
Supportive Cancer Therapy|July 18, 2008
Rapid and sustained influence of intravenous zoledronic Acid on course of pain and analgesics consumption in patients with cancer with bone metastases: a multicenter open-label study over 1 yearAlbrecht Kretzschmar, Thomas Wiege, Salah-Eddin Al-Batran, et al.
The Lancet. Oncology|October 11, 2016
IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trialBrian I Rini, Arnulf Stenzl, Romauld Zdrojowy, et al.
Nature Medicine|July 31, 2012
Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survivalSteffen Walter, Toni Weinschenk, Arnulf Stenzl, et al.
Pageof 1